On Friday, Dr. Krishna Ella, Founder Chairman of Bharat Biotech, stated that the company is currently working on an H3N2 vaccine amid the influenza virus in the country. Speaking outside of a one-day CII symposium titled "South India at 100: Moving Beyond Boundaries," Mr. Ella stated that he is an academic, and he and his team are undoubtedly going to address the H3N2 virus.

He added that a more effective H1N1 vaccine was developed by Bharat Biotech in 2015. H1N1 is also known as swine flu and is a subtype of the influenza A virus that causes respiratory infections. Early in March of this year, India experienced its first fatalities due to the influenza A subtype H3N2.

Earlier, the company had stated that it will be developing an antigen bank of 10 million doses as a stockpile for its COVID-19 nasal vaccine, iNOVACC. iNCOVACC, a recombinant, replication-deficient adenovirus vectored vaccine, was developed by the company in collaboration with Washington University in St. Louis. On the other hand, the inactivated virus intramuscular injectable vaccine Covaxin was developed by the company in collaboration with the Indian Council of Medical Research—National Institute of Virology (ICMR—NIV).

(Source: https://health.economictimes.indiatimes.com/news/pharma/amid-rising-viral-cases-bharat-biotech-working-on-h3n2-vaccine/98748236 )